These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

522 related items for PubMed ID: 16465660

  • 1. Costs and quality of life of patients with ankylosing spondylitis in Canada.
    Kobelt G, Andlin-Sobocki P, Maksymowych WP.
    J Rheumatol; 2006 Feb; 33(2):289-95. PubMed ID: 16465660
    [Abstract] [Full Text] [Related]

  • 2. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
    Kobelt G, Andlin-Sobocki P, Brophy S, Jönsson L, Calin A, Braun J.
    Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514
    [Abstract] [Full Text] [Related]

  • 3. The burden of ankylosing spondylitis in Spain.
    Kobelt G, Sobocki P, Mulero J, Gratacos J, Pocovi A, Collantes-Estevez E.
    Value Health; 2008 Sep; 11(3):408-15. PubMed ID: 18489666
    [Abstract] [Full Text] [Related]

  • 4. Costs and quality of life of patients with ankylosing spondylitis in Hong Kong.
    Zhu TY, Tam LS, Lee VW, Hwang WW, Li TK, Lee KK, Li EK.
    Rheumatology (Oxford); 2008 Sep; 47(9):1422-5. PubMed ID: 18635597
    [Abstract] [Full Text] [Related]

  • 5. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada.
    Kobelt G, Andlin-Sobocki P, Maksymowych WP.
    J Rheumatol; 2006 Apr; 33(4):732-40. PubMed ID: 16583476
    [Abstract] [Full Text] [Related]

  • 6. Costs and quality of life of multiple sclerosis in Austria.
    Kobelt G, Berg J, Lindgren P, Plesnilla C, Baumhackl U, Berger T, Kolleger H, Vass K.
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
    [Abstract] [Full Text] [Related]

  • 7. Costs and quality of life of multiple sclerosis in Switzerland.
    Kobelt G, Berg J, Lindgren P, Gerfin A, Lutz J.
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
    [Abstract] [Full Text] [Related]

  • 8. Costs and quality of life of multiple sclerosis in Spain.
    Kobelt G, Berg J, Lindgren P, Izquierdo G, Sánchez-Soliño O, Pérez-Miranda J, Casado MA, Associación Española de Esclerosis Múltiple.
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S65-74. PubMed ID: 17310340
    [Abstract] [Full Text] [Related]

  • 9. Costs and quality of life in multiple sclerosis in The Netherlands.
    Kobelt G, Berg J, Lindgren P, Anten B, Ekman M, Jongen PJ, Polman C, Uitdehaag B.
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
    [Abstract] [Full Text] [Related]

  • 10. Costs and quality of life of multiple sclerosis in Italy.
    Kobelt G, Berg J, Lindgren P, Battaglia M, Lucioni C, Uccelli A.
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S45-54. PubMed ID: 17310336
    [Abstract] [Full Text] [Related]

  • 11. [RAISE study observational and cross sectional study to evaluate the actual reality of the socio-economic impact of ankylosing spondylitis].
    Miranda L, Negreiro F, Queiroz MJ, Silva C.
    Acta Reumatol Port; 2008 Sep; 33(2):189-97. PubMed ID: 18604185
    [Abstract] [Full Text] [Related]

  • 12. A longitudinal study of disease activity and functional status in a hospital cohort of patients with ankylosing spondylitis.
    Robertson LP, Davis MJ.
    Rheumatology (Oxford); 2004 Dec; 43(12):1565-8. PubMed ID: 15353608
    [Abstract] [Full Text] [Related]

  • 13. Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial.
    Van Tubergen A, Boonen A, Landewé R, Rutten-Van Mölken M, Van Der Heijde D, Hidding A, Van Der Linden S.
    Arthritis Rheum; 2002 Oct 15; 47(5):459-67. PubMed ID: 12382292
    [Abstract] [Full Text] [Related]

  • 14. Costs and quality of life of multiple sclerosis in Germany.
    Kobelt G, Berg J, Lindgren P, Elias WG, Flachenecker P, Freidel M, König N, Limmroth V, Straube E.
    Eur J Health Econ; 2006 Sep 15; 7 Suppl 2():S34-44. PubMed ID: 17310337
    [Abstract] [Full Text] [Related]

  • 15. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
    Barkham N, Kong KO, Tennant A, Fraser A, Hensor E, Keenan AM, Emery P.
    Rheumatology (Oxford); 2005 Oct 15; 44(10):1277-81. PubMed ID: 16105913
    [Abstract] [Full Text] [Related]

  • 16. Costs and quality of life for patients with multiple sclerosis in Belgium.
    Kobelt G.
    Eur J Health Econ; 2006 Sep 15; 7 Suppl 2():S24-33. PubMed ID: 17318662
    [Abstract] [Full Text] [Related]

  • 17. Reference centile charts for measures of disease activity, functional impairment, and metrology in ankylosing spondylitis.
    Taylor AL, Balakrishnan C, Calin A.
    Arthritis Rheum; 1998 Jun 15; 41(6):1119-25. PubMed ID: 9627023
    [Abstract] [Full Text] [Related]

  • 18. Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy.
    Jauregui E, Conner-Spady B, Russell AS, Maksymowych WP.
    J Rheumatol; 2004 Dec 15; 31(12):2422-8. PubMed ID: 15570645
    [Abstract] [Full Text] [Related]

  • 19. Costs and quality of life of multiple sclerosis in Sweden.
    Berg J, Lindgren P, Fredrikson S, Kobelt G.
    Eur J Health Econ; 2006 Sep 15; 7 Suppl 2():S75-85. PubMed ID: 17310342
    [Abstract] [Full Text] [Related]

  • 20. Validation of the Tunisian versions of Bath Ankylosing Spondylitis Functional Index (BASFI) and Disease Activity Index (BASDAI).
    Kchir MM, Hamdi W, Kochbati S, Azzouz D, Daoud L, Saadellaoui K, Ghannouchi MM, Kaffel D, Ben Hamida A, Zouari B.
    Tunis Med; 2009 Aug 15; 87(8):527-30. PubMed ID: 20180357
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.